01.05.2024 - Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) - Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira . Seite 1
Hamilton, Bermuda, April 04, 2024 Altamira Therapeutics Ltd. , a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will.
Altamira Therapeutics shares are trading higher Monday after the company announced that it has entered into a collaboration agreement with Univercells Group to evaluate the use of the company's proprietary SemaPhore platform for the delivery of mRNA vaccines. Under the terms of the agreement, Univercells will test a proprietary mRNA vaccine delivered with Altamira's SemaPhore nanoparticle platform. If the experiments are successful, the companies intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells' production platform.